| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044820953 |
| P356 | DOI | 10.1038/KI.2011.477 |
| P698 | PubMed publication ID | 22358146 |
| P5875 | ResearchGate publication ID | 221854767 |
| P50 | author | Estela Paz-Artal | Q40630377 |
| Antonio Serrano | Q46790404 | ||
| P2093 | author name string | Manuel Serrano | |
| Elisa Ramírez | |||
| David Lora | |||
| Manuel Praga | |||
| Jose M Morales | |||
| Florencio García | |||
| Agustín Gómez de la Cámara | |||
| F Javier Alfaro | |||
| P2860 | cites work | International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 |
| Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I | Q28304443 | ||
| Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. | Q33576496 | ||
| IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus | Q33680556 | ||
| Structure-function studies on beta 2-glycoprotein I. | Q34021205 | ||
| Pathogenic mechanisms mediating antiphospholipid syndrome | Q34404108 | ||
| Cardiovascular complications in chronic kidney disease | Q35140917 | ||
| Antiphospholipid syndrome infectious origin | Q35680777 | ||
| Clinical laboratory testing for the antiphospholipid syndrome | Q36127208 | ||
| Cardiovascular risk in chronic renal disease and transplantation prevention and management | Q36161264 | ||
| Antiphospholipid syndrome and the kidneys | Q36502421 | ||
| IgA antibodies to beta2-glycoprotein I and atherosclerosis | Q36670050 | ||
| Insights into atherosclerosis therapy in antiphospholipid syndrome | Q36984674 | ||
| Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms | Q37249524 | ||
| Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients | Q37351603 | ||
| Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression | Q40957024 | ||
| Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease | Q44114961 | ||
| Effects of long and short hemodialysis on endothelial function: a short-term study | Q44358554 | ||
| Cardiovascular and noncardiovascular mortality among patients starting dialysis | Q44486693 | ||
| Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke | Q46520770 | ||
| Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women | Q61040663 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| Carotid atherosclerosis in chronic renal failure-the central role of increased plaque burden | Q79330118 | ||
| The antiphospholipid syndrome | Q79870443 | ||
| Antiphospholipid antibodies in acute coronary syndrome | Q80434476 | ||
| Influence of haemodialysis on early markers of atherosclerosis | Q81384088 | ||
| Mechanisms of anti-phospholipid antibody formation and action | Q83286175 | ||
| Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus | Q85206714 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| risk factor | Q1475848 | ||
| P304 | page(s) | 1239-1244 | |
| P577 | publication date | 2012-02-22 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality | |
| P478 | volume | 81 |
| Q36547962 | A potent multivalent vaccine for modulation of immune system in atherosclerosis: an in silico approach |
| Q38885685 | Anti-phospholipid Antibodies and Smoking: An Overview |
| Q47551794 | Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey |
| Q90312460 | Antiphospholipid Syndrome and Kidney Involvement: New Insights |
| Q37228076 | Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study |
| Q35124252 | Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I. |
| Q33431396 | Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events |
| Q38113521 | Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. |
| Q53094082 | Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. |
| Q84251492 | Does IgA antibody against β2 glycoprotein I increase cardiovascular risk in hemodialysis patients? |
| Q40643063 | Evaluation of three fully automated immunoassay systems for detection of IgA anti-beta 2-glycoprotein I antibodies |
| Q38646515 | Future research directions to improve fistula maturation and reduce access failure. |
| Q47229159 | IMMUNE RESPONSES OF HLA-HIGHLY-SENSITIZED AND NONSENSITIZED PATIENTS TO GENETICALLY-ENGINEERED PIG CELLS. |
| Q37522782 | Improving outcomes in patients with lupus and end-stage renal disease |
| Q40115024 | Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies. |
| Q37704874 | Isolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome |
| Q54982590 | Pretransplant IgA-Anti-Beta 2 Glycoprotein I Antibodies As a Predictor of Early Graft Thrombosis after Renal Transplantation in the Clinical Practice: A Multicenter and Prospective Study. |
| Q35716279 | Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease. |
| Q87467570 | Renal involvement in antiphospholipid syndrome |
| Q37730681 | Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease |
| Q41130615 | Repeated renal infarction in native and transplanted kidneys due to left ventricular thrombus formation caused by antiphospholipid antibody syndrome |
| Q51278559 | Study of β2-Glycoprotein I Polymorphisms in Patients With Chronic Renal Failure as a Predisposing Factor for the Development of Anti-β2-Glycoprotein I Auto-Antibodies. |
| Q36716833 | The Biology of Hemodialysis Vascular Access Failure |
| Q64255347 | The IgA Isotype of Anti-β2 Glycoprotein I Antibodies Recognizes Epitopes in Domains 3, 4, and 5 That Are Located in a Lateral Zone of the Molecule (L-Shaped) |
| Q90312450 | The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome |
| Q26775058 | The molecular mechanisms of hemodialysis vascular access failure |
Search more.